Veradermics’ stock up on male hair loss trial success
Veradermics’ stock was up nearly 6% at market open today after a Phase III trial evaluating its hair loss drug…
News
Lilly’s Omvoh leads to 50% clinical remission rate in paediatric UC
Zentalis reports survival data from azenosertib ovarian cancer study
Cyrano’s Phase II trial of CYR-064 meets primary safety endpoint
First patient dosed in MacroGenics’ Phase I MGC030 trial
Merz concludes enrolment in Phase III Xeomin trials for migraine
Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC
Vanda puts anxiety drug’s development on ice after Phase III fail
